BioNano Genomics Inc vs Nerdwallet Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Nerdwallet Inc trades at $9.17 (market cap $616.53M). The key difference: Nerdwallet Inc is far larger — about 46.7× BioNano Genomics Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NRDS | |
|---|---|---|
Market Cap | $13.20M | $616.53M |
Sector | Health | Financials |
52-Week High | $4.92 | $15.93 |
52-Week Low | $1.09 | $7.58 |
Enterprise Value | $15.81M | $530.83M |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
NerdWallet (NRDS) trades at $9.49, up 0.21% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported revenue of $836.6M in 2025, with net income of $48.7M and a net margin of 5.82%, showing a clear turnaround from losses in prior years. Recent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected, underscore operational strength. Analyst consensus is bullish with a $12.75 price target, implying 34% upside.
The outlook is positive given valuation multiples like a P/E of 10.2 and EV/EBITDA of 3.87, which appear attractive relative to growth. Key risks include reliance on search-driven traffic and macroeconomic sensitivity. Continued execution on revenue diversification and cost control supports further upside, but investors should monitor competitive pressures and consumer spending trends.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →